logo
  

Monster Worldwide Q4 Profit Tops Estimates - Quick Facts

Monster Worldwide Inc. (MWW) reported a fourth-quarter net loss to company of $289.72 million or $3.31 per share, compared to a loss of $20.12 million or $0.21 per share, prior year. The company noted that its GAAP per share result included a net of tax non-cash goodwill impairment charge of $263 Million. Non-GAAP net income attributable to Monster was $6 million or $0.07 per share, for the quarter.

On average, seven analysts polled by Thomson Reuters expected the company to report profit per share of $0.06 for the quarter. Analysts' estimates typically exclude special items.

Revenue decreased to $186.20 million from $198.72 million last year. Analysts expected revenue of $192.62 million for the quarter.

The company expects first quarter non-GAAP EPS from continuing operations to be in the range of $0.05 to $0.09. Analysts expect the company to report first-quarter earnings per share of $0.07.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT